Revance Therapeutics, Inc.
NASDAQ:RVNC
5.81 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities: | |||||||||||||
Net Income
| -323.986 | -356.422 | -281.31 | -282.089 | -159.429 | -142.568 | -120.587 | -89.27 | -73.476 | -62.917 | -52.448 | -58.259 | -44.863 |
Depreciation & Amortization
| 13.693 | 39.146 | 19.853 | 10.25 | 2.909 | 1.726 | 1.468 | 1.445 | 1.995 | 2.051 | 1.881 | 1.777 | 1.983 |
Deferred Income Tax
| -99.547 | 0 | 0.089 | -2.72 | -2.645 | -2.569 | 3.928 | 10.878 | 0.512 | 8.715 | -1.343 | 1.283 | -0.48 |
Stock Based Compensation
| 49.187 | 52.34 | 43.434 | 36.453 | 17.922 | 16.273 | 13.23 | 11.953 | 12.388 | 6.53 | 0.548 | 0.079 | 0.273 |
Change In Working Capital
| -43.882 | 0.665 | -4.774 | 39.972 | 34.272 | 22.717 | 6.443 | 2.761 | 2.524 | -3.159 | -2.854 | -7.126 | -0.066 |
Accounts Receivables
| -16.338 | -7.99 | -1.519 | 12.137 | 27 | -26.952 | 0.08 | 0.03 | 0 | 0 | 0 | 0 | 0 |
Inventory
| -14.91 | -6.008 | -4.278 | -5.876 | -27 | -3.173 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Payables
| 6.9 | -5.448 | -1.824 | 4.425 | -0.36 | 1.691 | 2.607 | 0.953 | -0.692 | -3.399 | 3.193 | 1.028 | -0.636 |
Other Working Capital
| -19.534 | 20.111 | 2.847 | 29.286 | 34.632 | 51.151 | 3.836 | 1.808 | 3.216 | 0.24 | -6.047 | -8.154 | 0.57 |
Other Non Cash Items
| 189.334 | 70.723 | 1.17 | 19.632 | 0.81 | 0.175 | 0.176 | 2.406 | 0.388 | -6.293 | 6.458 | 23.332 | 14.74 |
Operating Cash Flow
| -216.575 | -193.548 | -221.538 | -178.502 | -106.161 | -104.246 | -95.342 | -59.827 | -55.669 | -55.073 | -47.758 | -38.914 | -28.413 |
Investing Activities: | |||||||||||||
Investments In Property Plant And Equipment
| -6.886 | -23.01 | -18.075 | -4.216 | -3.238 | -7.091 | -2.625 | -3.47 | -3.328 | -6.975 | -6.477 | -0.319 | -0.15 |
Acquisitions Net
| 0 | 19.8 | 7.7 | -0.818 | 0.008 | 0.1 | 0.1 | 1.8 | 0 | 0 | 0 | 0 | 0 |
Purchases Of Investments
| -263.923 | -347.966 | -183.59 | -259.304 | -331.362 | -314.911 | -36.028 | -280.681 | -54.087 | 0 | 0 | 0 | 0 |
Sales Maturities Of Investments
| 385.432 | 232.178 | 172 | 276.469 | 317 | 213.435 | 157.445 | 208.65 | 1 | 0 | 0 | 0 | 0 |
Other Investing Activites
| -4.883 | -19.8 | -7.7 | 17.047 | -14.362 | 1.441 | -0.1 | -1.798 | 0.075 | 0.075 | 0.075 | 0.075 | 0.075 |
Investing Cash Flow
| 109.74 | -138.798 | -29.665 | 12.131 | -17.592 | -107.026 | 118.792 | -75.499 | -56.34 | -6.9 | -6.402 | -0.244 | -0.075 |
Financing Activities: | |||||||||||||
Debt Repayment
| -30.16 | -11.097 | 0 | -278.31 | 0 | -0.932 | -3.636 | -3.541 | -5.25 | -5.794 | -8.576 | -4.557 | -13.083 |
Common Stock Issued
| 114.623 | 248.014 | 38.054 | 83.948 | 222.84 | 4.926 | 196.228 | 1.406 | 136.251 | 234.552 | 0 | 0 | 0 |
Common Stock Repurchased
| -8.216 | -6.496 | -8.185 | -8.441 | -1.378 | -2.212 | -0.573 | -0.507 | -0.993 | 0 | 0 | 0 | 0 |
Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing Activities
| 52.104 | 107.769 | 38.054 | 804.156 | 0.195 | 2.714 | 3.352 | 0.899 | 11.591 | 234.885 | 62.567 | 18.177 | 67.15 |
Financing Cash Flow
| 136.567 | 331.694 | 29.869 | 331.484 | 221.657 | 1.782 | 195.944 | -2.642 | 142.592 | 229.091 | 53.991 | 13.62 | 54.067 |
Other Information: | |||||||||||||
Effect Of Forex Changes On Cash
| -0.818 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net Change In Cash
| 28.914 | -0.652 | -221.334 | 165.113 | 97.904 | -209.49 | 219.394 | -137.968 | 30.583 | 167.118 | -0.169 | -25.538 | 25.579 |
Cash At End Of Period
| 137.879 | 115.017 | 115.669 | 337.003 | 171.89 | 73.986 | 283.476 | 64.082 | 201.615 | 171.032 | 3.914 | 4.083 | 29.621 |